Literature DB >> 24657498

Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer.

Jingying Hou1, Zhong Yu1, Rengyun Xiang1, Chuqiang Li1, Lin Wang1, Shufen Chen1, Qingyun Li1, Mei Chen1, Linyun Wang2.   

Abstract

BACKGROUND: Substantial evidence suggests that the expansion of regulatory T cells (T(regs)) plays a pivotal role in immunological evasion of tumors. Recent studies have demonstrated that a majority of tumor cells overexpress B7-H1, and this overexpression is associated with poor disease prognosis. Although an increase of T(regs) and B7-H1 has been revealed in several malignancies, their correlation in gastric cancer has not been studied.
METHODS: Tumor sections from 111 gastric cancer patients were stained for FOXP3 and B7-H1 by immunohistochemistry. The expression levels of these two molecules were statistically associated with various factors involved in disease progression and prognosis. The correlation between their expression levels was analyzed.
RESULTS: The infiltration of FOXP3(+) T(regs) and expression of B7-H1 were observed in gastric cancer tissues, and there was a highly significant correlation between these two molecules (P < 0.01). The expression of FOXP3(+) T(regs) and B7-H1 was associated with lymph node metastasis and the clinicopathological stage and prognosis of gastric cancer patients. The expression levels of these two determinants in patients with lymph node metastasis and an advanced clinicopathological stage were distinctly higher (P < 0.05). The patients with enhanced expression of FOXP3(+) T(regs) and B7-H1 exhibited a lower overall survival rate and a worse prognosis (P < 0.05).
CONCLUSIONS: Increased expression of FOXP3(+) T(regs) and B7-H1 was observed in gastric cancer tissues; the two molecules were closely correlated with each other, suggesting that they might be used as new biomarkers to predict the disease progression and prognosis. Combinatorial immunotherapeutic approaches based on depleting the T(regs) and blocking B7-H1 might improve therapeutic efficacy in gastric cancer.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B7-H1; Clinicopathology; Correlation; FOXP3(+) T(regs); Gastric cancer; Prognosis

Mesh:

Substances:

Year:  2014        PMID: 24657498     DOI: 10.1016/j.yexmp.2014.03.005

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  61 in total

1.  Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.

Authors:  Riccardo Giampieri; Elena Maccaroni; Alessandra Mandolesi; Michela Del Prete; Kalliopi Andrikou; Luca Faloppi; Alessandro Bittoni; Maristella Bianconi; Marina Scarpelli; Raffaella Bracci; Mario Scartozzi; Stefano Cascinu
Journal:  Gastric Cancer       Date:  2016-01-21       Impact factor: 7.370

Review 2.  Immunotherapy in gastrointestinal cancers.

Authors:  Patrick Grierson; Kian-Huat Lim; Manik Amin
Journal:  J Gastrointest Oncol       Date:  2017-06

3.  CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer.

Authors:  Shu Su; Zhengyun Zou; Fangjun Chen; Naiqing Ding; Juan Du; Jie Shao; Lin Li; Yao Fu; Bian Hu; Yang Yang; Huizi Sha; Fanyan Meng; Jia Wei; Xingxu Huang; Baorui Liu
Journal:  Oncoimmunology       Date:  2016-11-22       Impact factor: 8.110

4.  Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact.

Authors:  Joo Yeon Kim; Woo Gyeong Kim; Chae Hwa Kwon; Do Youn Park
Journal:  Gastric Cancer       Date:  2019-05-31       Impact factor: 7.370

5.  Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma.

Authors:  Kazuto Harada; Xiaochuan Dong; Jeannelyn S Estrella; Arlene M Correa; Yan Xu; Wayne L Hofstetter; Kazuki Sudo; Hisashi Onodera; Koyu Suzuki; Akihiro Suzuki; Randy L Johnson; Zhenning Wang; Shumei Song; Jaffer A Ajani
Journal:  Gastric Cancer       Date:  2017-08-11       Impact factor: 7.370

Review 6.  Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations.

Authors:  Alexander G Raufi; Samuel J Klempner
Journal:  J Gastrointest Oncol       Date:  2015-10

Review 7.  The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1.

Authors:  Zhaohui Jin; Harry H Yoon
Journal:  J Gastrointest Oncol       Date:  2016-10

Review 8.  Helicobacter pylori Deregulates T and B Cell Signaling to Trigger Immune Evasion.

Authors:  Victor E Reyes; Alex G Peniche
Journal:  Curr Top Microbiol Immunol       Date:  2019       Impact factor: 4.291

9.  Correlation between FOXP3 expression and gastric cancer.

Authors:  Guoxiao Guo; Zhikuan He; Zhaohui Shi
Journal:  Oncol Lett       Date:  2016-06-17       Impact factor: 2.967

10.  Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer.

Authors:  Naoki Takahashi; Satoru Iwasa; Yusuke Sasaki; Hirokazu Shoji; Yoshitaka Honma; Atsuo Takashima; Natsuko Tsuda Okita; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada
Journal:  J Cancer Res Clin Oncol       Date:  2016-06-02       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.